Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Amrn | History Defined

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

Amarin Corporation (NASDAQ:AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovascular drug VAZKEPA (icosapent ethyl) across 59 countries in Europe.

Benzinga · Jun 24, 2025

Amarin Outlines $100M Cost Saving Plan

Amarin Outlines $100M Cost Saving Plan

Amarin Corporation plc (NASDAQ:AMRN) announced a comprehensive cost and organizational restructuring plan to reduce operating costs by approximately $100 million over the next 12 months. The restructuring will enable Amarin to maintain a positive contribution margin in the U.S. while investing in its European market launches and global expansion for Vascepa/Vazkepa. The majority…

Benzinga · Jun 6, 2022

Looking Into Amarin Corp's Return On Capital Employed

Looking Into Amarin Corp's Return On Capital Employed

Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million.

Benzinga · May 16, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Amarin Shares Are Plunging After Q1 Earnings

Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations.

Benzinga · May 4, 2022

Recap: Amarin Corp Q1 Earnings

Amarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

Amarin Corp's Earnings: A Preview

Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp will report an earnings per share (EPS) of $-0.02.

Benzinga · May 3, 2022

Looking Into Amarin Corp's Return On Capital Employed

According to Benzinga Pro, during Q4, Amarin Corp (NASDAQ:AMRN) earned $14.70 million, a 211.76% increase from the preceding quarter. Amarin Corp also posted a total of $144.49 million in sales, a 1.73% increase since Q3.

Benzinga · Mar 2, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Coverage From

Benzinga

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

423,951 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play